Dr. Alicia Broderick OpEd on Autism Awareness Month

Dr. Alicia Broderick, Teaching and Learning Professor, wrote an opinion piece published on NJ.com about Autism Awareness Month.

She wrote:

Autism acceptance month: Raising awareness or manufacturing a market? | Opinion

This April, you’ll once again see the now-familiar icons and ritualized observances that have marked April as “autism awareness” month for decades: the puzzle pieces, the “Light it Up Blue” campaign, the now rainbow-themed branding of ribbons, t-shirts and other sundry kitsch, and, perhaps most importantly–the fundraising campaigns. You’ll be asked to “take the pledge,” “celebrate differences,” maybe even “learn the signs.”

But here’s what you’re less likely to see or hear about this month, and it’s one of the most important things about which we need to be raising critical awareness: the industrial-scale commodification of autistic people. And how these initiatives are actually part of the money-making machine.

While Autism Awareness Month has been celebrated for more than 50 years, the last decade and a half’s “awareness” initiatives and their fear-mongering rhetoric — autism is an enemy, it’s an epidemic, and it’s coming for your children — were masterfully crafted to generate a market of willing and eager consumers: consumers of autism intervention products. That’s not raising awareness, that’s manufacturing a market.

Since at least 2011, the autistic community has decried these events each April, and has advocated instead for the acceptance and valuing of the autistic experience, and the nurturing of autistic agency, liberation, and pride.

By 2021, many (though not all) of the largest autism advocacy organizations had jettisoned their “autism awareness” initiatives and rebranded to get on board with April as “Autism Acceptance Month” (and many are also busily appropriating the language and iconography of “neurodiversity” into their own PR, logos, and brands.)

But before we celebrate this as a victory for autistic activism, let’s ask why (or why now)?

Why this kinder, gentler, shift to autism acceptance, to valuing of neurodiversity?

Perhaps as a society we have genuinely experienced growth, and that is almost certainly true, to a certain extent. But that’s not the only reason.

The other answer is that it now benefits the autism industries to rebrand.

And the “valuing of autistic people” branding serves at least in part to obscure the “value” of autistic people as commodities for the autism industries.

It’s about the money. It has been and it always will be.

Within autism commerce, autistic people, including very young children, have become the raw materials of the profitable, booming and ever-diversifying autism industries, including the applied behavior analysis industry, the autism pharmaceutical industry, and others. And the central engine driving the growth of those (multibillion-dollar/year) industries is their vast potential for profit.

Every autistic 2-year-old sets in motion a chain of commercial transactions: consultations, evaluations, diagnoses; infinite varieties of therapies, supports, services, counseling and other interventions, as well as pharmaceuticals and even research dollars.

The minute a child is diagnosed, they are transformed into a commodity of the autism industries, representing nearly boundless potential for profit extraction.

Wall Street is certainly no stranger to this market. Research firms are producing bullish forecasts for the autism intervention industries

(both ABA intervention and pharmaceutical intervention subsectors), while private equity and venture capital firms are aggressively acquiring autism-related assets.

There’s even a meet-and-greet summit later this month that puts LLCs selling autism interventions (mostly ABA) in direct conversation with private equity firms, venture capitalists and other potential investors.

For the last 30 years, behavioral intervention services have dominated, and virtually monopolized, the marketplace (just try getting public education dollars or health insurance dollars ).

And pharmaceutical intervention is on the cusp of its own growth spurt, staking out its own market share.

The autism markets are booming, and they are globalizing. However, the substantial and ever-increasing investment and growth in these industries is not centrally driven by what’s best, ethical, right or just for, let alone desired by, autistic people. The engine of that growth, rather, is driven by the industries’ vast potential for profit generation. Period.

Awareness isn’t inherently negative but we have to ask, “awareness of what?” Greater awareness of the commodification of autistic people would be a good thing if that awareness leads to a disruption of those processes. And acceptance isn’t inherently positive if it’s used as a shiny object to groom consumption and brand loyalty and to distract from asking the hard questions. This isn’t a binary consideration.

We should always ask — and not just every April — who benefits?

The booming autism industries ultimately may or may not improve the lives of autistic people. But they certainly seem to be benefiting the many non-autistic people who profit from their existence.

And who benefits? more than anything else you’ll hear this month is the question we need to be asking as we focus our attention on autism.